Oncolytics Biotech, Inc. (NASDAQ:ONCY) saw a significant decrease in short interest in January. As of January 31st, there was short interest totalling 1,560,000 shares, a decrease of 10.3% from the January 15th total of 1,740,000 shares. Approximately 6.0% of the company’s shares are short sold. Based on an average daily volume of 1,670,000 shares, the days-to-cover ratio is presently 0.9 days.
NASDAQ:ONCY traded up $0.03 during midday trading on Friday, hitting $2.59. The stock had a trading volume of 779,922 shares, compared to its average volume of 1,537,206. Oncolytics Biotech has a one year low of $0.35 and a one year high of $6.02. The company has a market capitalization of $83.39 million, a price-to-earnings ratio of -3.55 and a beta of 2.99. The stock has a 50-day moving average of $3.23 and a 200 day moving average of $1.48. The company has a quick ratio of 3.78, a current ratio of 3.78 and a debt-to-equity ratio of 0.07.
Oncolytics Biotech (NASDAQ:ONCY) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.07. On average, sell-side analysts anticipate that Oncolytics Biotech will post -0.74 earnings per share for the current fiscal year.
A number of large investors have recently made changes to their positions in ONCY. Cedar Mountain Advisors LLC bought a new stake in Oncolytics Biotech during the 4th quarter valued at $27,000. Crescent Grove Advisors LLC bought a new stake in Oncolytics Biotech during the 4th quarter valued at $51,000. Jane Street Group LLC bought a new stake in Oncolytics Biotech during the 4th quarter valued at $69,000. Finally, CIBC World Markets Inc. bought a new stake in Oncolytics Biotech during the 4th quarter valued at $82,000. 1.15% of the stock is currently owned by institutional investors.
Several research analysts recently issued reports on ONCY shares. Zacks Investment Research raised Oncolytics Biotech from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a research note on Saturday, November 16th. ValuEngine cut Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Tuesday, February 4th. Finally, Roth Capital increased their price objective on Oncolytics Biotech from $6.80 to $9.00 and gave the stock a “buy” rating in a research note on Thursday, January 2nd.
About Oncolytics Biotech
Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.
Read More: What is a Call Option?
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.